// App-Quantinova.ai

OP0216 : DEVELOPMENT AND VALIDATION OF PATIENT-LEVEL PREDICTION MODELS FOR ADVERSE HEALTH OUTCOMES AMONGST ADULT RA PATIENTS INITIATING FIRST-LINE TREATMENT OF METHOTREXATE MONOTHERAPY: A MULTINATIONAL REAL-WORLD COHORT ANALYSIS INCLUDING 164,735 SUBJECTS

Researchers

Presenter

  • C. Yang

Principal Investigators

  • R. Williams

  • J. Swerdel

  • M. Jani

  • T. Duarte-Salles

  • K. Chatzidionysiou

  • D. Prieto-Alhambra

  • P. Ryan

  • P. Rijnbeek

Medical Centers

  • Department of Medical Informatics and Radiology, Erasmus MC, Rotterdam, Netherlands,

  • Janssen Research and Development, Titusville, New Jersey, United States of America

  • Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom

  • Fundació Inst. Univ.ri per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain

  • Dep of Medicine, Solna, Rheum Unit, Karolinska Institutet, Stockholm, Sweden

  • University of Oxford, Oxford, United Kingdom

  • Johnson & Johnson, New Jersey, United States of America

  • Erasmus University, Department of Medical Informatics, Rotterdam, Netherlands

Locations

  • Netherlands

  • United States

  • United Kingdom

  • Spain

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

Disease

  • Stroke

  • Acro–dermato–ungual–lacrimal–tooth (ADULT) syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved